Prediction of likelihood of cancer recurrence
View Patent ↗The present invention provides gene sets, the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
1. A method comprising: assaying a level of a RNA transcript of CTSL2 in a tissue sample obtained from a breast tumor of a human patient; normalizing said level against a level of at least one reference RNA transcript in said tissue sample to provide a normalized CTSL2 expression level; and predicting a likelihood of breast cancer recurrence for said patient by comparing said normalized CTSL2 expression level to gene expression data from reference samples derived from breast tumors of breast cancer patients, wherein said gene expression data comprises data for CTSL2 and wherein increased normalized expression level of CTSL2 is positively correlated with increased likelihood of breast cancer recurrence in said patients.
2. The method of claim 1 further comprising assaying a level of a RNA transcript of GRB7 in said tissue sample; normalizing the level of said RNA transcript of GRB7 against a level of at least one reference RNA transcript in said tissue sample to provide a normalized GRB7 expression level; and comparing said normalized GRB7 expression level to gene expression data obtained from said reference samples derived from breast tumors of breast cancer patients, wherein increased normalized expression of GRB7 positively correlates to an increased likelihood of breast cancer recurrence in said patients.
3. The method of claim 1 wherein said breast tumor is an invasive breast tumor.
4. The method of claim 3 , wherein said breast tumor is a node negative, ER positive breast tumor.
5. The method of claim 1 wherein said RNA transcript is an mRNA transcript.
6. The method of claim 1 wherein said tissue sample is a fixed, wax-embedded breast cancer tissue specimen of said patient.
7. The method of claim 1 wherein said tissue sample is a core biopsy or fine needle aspirate.
8. The method of claim 1 , further comprising generating a report indicating a likelihood of long-term survival without breast cancer recurrence of said human patient.
9. The method of claim 1 , wherein said assaying is done using RT-PCR.
10. The method of claim 8 wherein said report includes information to support a recommendation of a treatment modality for said patient.
11. The method of claim 1 , wherein said gene expression data is produced using a multivariate analysis using the Cox Proportional Hazards model or a t-test.
12. The method of claim 1 , further comprising predicting a likelihood of long-term survival without breast cancer recurrence of said human patient using the predicted likelihood of breast cancer recurrence for said human patient.